This company has been marked as potentially delisted and may not be actively trading. NYSE:MYOV Myovant Sciences (MYOV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Myovant Sciences Stock (NYSE:MYOV) Get Myovant Sciences alerts:Sign Up Key Stats Today's Range$26.98▼$27.0050-Day Range$26.88▼$26.9952-Week Range$7.67▼$27.06Volume2.26 million shsAverage Volume1.17 million shsMarket Capitalization$2.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. Read More Receive MYOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYOV Stock News HeadlinesMyovant Sciences Stock Price HistoryJune 2, 2025 | investing.comVivek Ramaswamy's Net Worth: How Donald Trump's Key Aide Made His BillionsNovember 13, 2024 | msn.comNever thought I’d see thisPorter Stansberry — founder of one of the world’s largest financial research firms — believes we’re entering a historic economic shift he calls The Final Displacement. Backed by warnings from Nobel Prize winners, this rare event could reshape everything from markets to personal wealth, just as past global displacements toppled empires and created new fortunes. His new investigation reveals why it’s unfolding now, what’s driving it, and how to position yourself on the right side of history.October 22 at 2:00 AM | Porter & Company (Ad)Born To Indian Immigrants, Now Part Of Trump's 'DOGE' Plan – How Vivek Ramaswamy Became A Billionaire By Shedding Unprofitable Pharma AssetsNovember 13, 2024 | msn.comGlobal Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12% by 2030 | DelveInsightSeptember 25, 2024 | finance.yahoo.comThe Scientific Establishment Is Turning 'Science' Into a Dogmatic Tool of Oppression | OpinionSeptember 11, 2024 | newsweek.comNInovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | msn.comGynecology Collaboration, R&D, and Licensing Deals Trends Report 2024May 7, 2024 | finance.yahoo.comSee More Headlines MYOV Stock Analysis - Frequently Asked Questions How were Myovant Sciences' earnings last quarter? Myovant Sciences Ltd. (NYSE:MYOV) posted its quarterly earnings results on Tuesday, October, 26th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.11. The business earned $77.90 million during the quarter, compared to the consensus estimate of $72.67 million. When did Myovant Sciences IPO? Myovant Sciences (MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers. What other stocks do shareholders of Myovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myovant Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings10/26/2021Today10/22/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MYOV Previous SymbolNASDAQ:MYOV CIK1679082 Webwww.myovant.com Phone442074003351FaxN/AEmployees407Year Founded2016Profitability EPS (Trailing Twelve Months)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$205.98 million Net Margins-48.47% Pretax Margin-42.81% Return on EquityN/A Return on Assets-39.36% Debt Debt-to-Equity RatioN/A Current Ratio1.57 Quick Ratio1.45 Sales & Book Value Annual Sales$230.97 million Price / Sales11.36 Cash FlowN/A Price / Cash FlowN/A Book Value($5.04) per share Price / Book-5.35Miscellaneous Outstanding Shares97,240,000Free Float95,388,000Market Cap$2.62 billion OptionableNot Optionable Beta2.17 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:MYOV) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myovant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
